Cuando Grecia nos "alcance"...o de la Responsabilidad Social Corporativa (RSC).

Pharmaceuticals: facing a Greek tragedy

.../...

As a result of last year's price cuts, Roche began withholding some shipments of non-emergency medicine to some of the most indebted healthcare providers after providers attempted to settle drug bills with Greek government bonds. Other companies, including Sanofi and GlaxoSmithKline, are said to be also withholding shipments or negotiating with the Greek government to recoup some debt payments, while Novo Nordisk and Leo Pharma have pulled a number of drugs from the market. The latest round of price cuts will also certainly fuel parallel trade out of Greece and could ultimately lead to drug shortages, while any price cuts in the country will also negatively affect other markets, such as Turkey, that reference Greek drug prices. In response, pharmaceutical companies could consider adopting strategies such as delaying any proposed brand launches in Greece until further notice, withdrawing high-value products from the market if price cuts go ahead, making wider use of direct-to-pharmacy supply-chain strategies or dual pricing structures to reduce the impact of parallel trade, or simply preparing for the sales of key brands to be impacted.

Tomado de

Pharmaceuticals: facing a Greek tragedy / Datamonitor 30.6.2011